These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 11480559

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY, Yang CH, Chen YC.
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [Abstract] [Full Text] [Related]

  • 4. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY.
    Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH.
    J Natl Cancer Inst; 1998 Jan 21; 90(2):124-33. PubMed ID: 9450572
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
    Wang ZG, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP, Pandolfi PP.
    Blood; 1998 Sep 01; 92(5):1497-504. PubMed ID: 9716575
    [Abstract] [Full Text] [Related]

  • 9. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
    Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z.
    Blood; 1996 Aug 01; 88(3):1052-61. PubMed ID: 8704214
    [Abstract] [Full Text] [Related]

  • 10. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM, He LZ, Warrell RP, Wang ZG, Pandolfi PP.
    Proc Natl Acad Sci U S A; 2000 Aug 29; 97(18):10173-8. PubMed ID: 10954752
    [Abstract] [Full Text] [Related]

  • 11. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
    Jing Y.
    Leuk Lymphoma; 2004 Apr 29; 45(4):639-48. PubMed ID: 15160934
    [Abstract] [Full Text] [Related]

  • 12. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
    Yan H, Peng ZG, Wu YL, Jiang Y, Yu Y, Huang Y, Zhu YS, Zhao Q, Chen GQ.
    Haematologica; 2005 Dec 29; 90(12):1607-16. PubMed ID: 16330433
    [Abstract] [Full Text] [Related]

  • 13. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
    Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z.
    Blood; 1997 May 01; 89(9):3345-53. PubMed ID: 9129041
    [Abstract] [Full Text] [Related]

  • 14. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
    Koken MH, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A, Minard P, Degos L, Varet B, de Thé H.
    Oncogene; 1999 Jan 28; 18(4):1113-8. PubMed ID: 10023688
    [Abstract] [Full Text] [Related]

  • 15. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
    Wang QQ, Zhou XY, Zhang YF, Bu N, Zhou J, Cao FL, Naranmandura H.
    Oncotarget; 2015 Sep 22; 6(28):25646-59. PubMed ID: 26213848
    [Abstract] [Full Text] [Related]

  • 16. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
    Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H, Naoe T.
    Leukemia; 2000 Oct 22; 14(10):1743-50. PubMed ID: 11021749
    [Abstract] [Full Text] [Related]

  • 17. Arsenic trioxide: acute promyelocytic leukemia and beyond.
    Bachleitner-Hofmann T, Kees M, Gisslinger H.
    Leuk Lymphoma; 2002 Aug 22; 43(8):1535-40. PubMed ID: 12400595
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.